DE3786705D1 - Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren. - Google Patents

Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren.

Info

Publication number
DE3786705D1
DE3786705D1 DE8787106439T DE3786705T DE3786705D1 DE 3786705 D1 DE3786705 D1 DE 3786705D1 DE 8787106439 T DE8787106439 T DE 8787106439T DE 3786705 T DE3786705 T DE 3786705T DE 3786705 D1 DE3786705 D1 DE 3786705D1
Authority
DE
Germany
Prior art keywords
interleukin
inhibitor
treatment
ornithin
decarboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787106439T
Other languages
English (en)
Inventor
Terry R Bowlin
Sai P Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE3786705D1 publication Critical patent/DE3786705D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE8787106439T 1986-05-06 1987-05-04 Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren. Expired - Lifetime DE3786705D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86016686A 1986-05-06 1986-05-06

Publications (1)

Publication Number Publication Date
DE3786705D1 true DE3786705D1 (de) 1993-09-02

Family

ID=25332641

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787106439T Expired - Lifetime DE3786705D1 (de) 1986-05-06 1987-05-04 Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren.

Country Status (6)

Country Link
EP (1) EP0248217B1 (de)
JP (1) JPS62263127A (de)
AT (1) ATE91899T1 (de)
CA (1) CA1318586C (de)
DE (1) DE3786705D1 (de)
PH (1) PH23658A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
ZA903804B (en) * 1989-05-23 1991-03-27 Merrell Dow Pharma A method of potentiating cell-mediated immunity utilizing polyamine derivatives
FR2706255B1 (fr) * 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
FR2706254B1 (fr) * 1993-06-17 1995-08-25 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines.
WO2018004467A1 (en) * 2016-07-01 2018-01-04 Agency For Science, Technology And Research A wound healing composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651442A (en) * 1979-10-01 1981-05-09 Mitsubishi Chem Ind Ltd Ornithine derivative
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors

Also Published As

Publication number Publication date
CA1318586C (en) 1993-06-01
ATE91899T1 (de) 1993-08-15
EP0248217A2 (de) 1987-12-09
PH23658A (en) 1989-09-27
EP0248217A3 (en) 1989-11-08
JPS62263127A (ja) 1987-11-16
EP0248217B1 (de) 1993-07-28

Similar Documents

Publication Publication Date Title
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE275948T1 (de) Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung
ATE89723T1 (de) Retinoide zur behandlung lichtgeschaedigter haut.
ES2007341A6 (es) Un procedimiento para producir m-csf
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
DE69328910D1 (de) Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore
EP0350036A3 (de) Hematoporphyrin zur topischen Anwendung
ATE173401T1 (de) Neue verwendung von 1-alpha-hydroxylierten-19-nor-vitamin-d-verbind ngen zur behandlung von psoriasis
ATE330613T1 (de) Verwendung von prostaglandin a oder dessen derivaten zur behandlung von psoriasis
ATE63815T1 (de) Verwendung von zinn-protoporphyrin und zinnmesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE3786705D1 (de) Verwendung eines ornithin-decarboxylate-inhibitors zur herstellung eines praeparats fuer die behandlung, zusammen mit lak-zellen und interleukin-2, von tumoren.
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE59407809D1 (de) Tumorizide t-lymphozyten
ATE116849T1 (de) Pharmazeutische verwendung von fettsäuren.
ATE57095T1 (de) Verwendung von hydroxyindolderivaten zur herstellung eines arzneimittels zur senkung des blutdrucks.
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
ATE197545T1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
KR890000108A (ko) 종양 치료용 약제학적 조성물
ES8205190A1 (es) Un procedimiento para la preparacion del acido 3,7,11,15-tetrametil-2,4,6,10-14-hexadecapentaenoico.
ATE23112T1 (de) Verwendung von 1-(p-isopropoxyethoxymethylphenoxy)-3-isopropylamino-propan-2-ol zur herstellung eines arzneimittels zur senkung des augeninnendrucks.
ATE83480T1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.

Legal Events

Date Code Title Description
8332 No legal effect for de